Professor Yadollah Omidi obtained his pharmacy doctorate (PharmD) degree from Tabriz University of Medical Sciences (TUOMS), Tabriz, Iran (1991), and his PhD degree in the field of brain drug delivery and targeting, “Blood-brain barrier: studies of novel cell-based in vitro models and carrier-mediated transporters” from Cardiff University, Cardiff, UK (2003). From Dec. 2002 to July 2004, he worked as postdoctoral research associate, studying gene-based nanomedicines and toxicogenomics at the Welsh School of Pharmacy, Cardiff University.
In 2005, Dr. Omidi founded the Research Center for Pharmaceutical Nanotechnology (RCPN) at TUOMS - the first national center for nanomedicine researches. Under his directorship, RCPN has been ranked as the national center of excellence for pharmaceutical/biomedical researches (2008-2011, 2013). In 2008, he founded the School of Advanced Biomedical Sciences at TUOMS. He acted as the director of RCPN until July 2011 when he moved to the US to work at the University of Pennsylvania (UPenn). His research activities are focused on different areas of pharmaceutical sciences in particular targeted therapeutics such as multifunctional nanomedicines and theranostics. As of 2003, he has published over 150 papers in peer-reviewed international journals such as Brain Res, Pharm Res, J Drug Target, J Controlled Release, Int J Nanomed, J Pharm Sci, J Biomed Nanotech, Biodrugs, etc. Dr Omidi is author of 16 book chapters. His works have been cited over 3250 times and his h-index is 31.
He has over 15 years of experience in pharmacy and medical schools, teaching different subjects (Pharmaceutics, Biopharmaceutics, Pharmacogenetics, Pharmaceutical Nanotechnology and Pharmaceutical Biotechnology) and supervising MSc, PharmD, MD and PhD students. In 2011, Dr. Omidi founded “BioImpacts” which is an international peer-review multidisciplinary access free-publish free journal for publication of biomedical and pharmaceutical researches - a publication platform for bench-to-bedside researches. Dr Omidi also acts as the editorial board of several journals such as Biologicals.
In 2011, he joined the Ovarian Cancer Research Center (OCRC), Perelman School of Medicine, University of Pennsylvanian (Philadelphia, USA) as a Visiting Associate Professor to undertake a translational research approach towards development of multifunctional nanomedicines and theranostics for targeted therapy of ovarian cancer with a particular focus on targeting of tumor microenvironment.
Follow Dr. Y. Omidi's publications through
Google Scholar; Scopus; PubMed;
ISI Web of Knowledge
Scopus ID: 6508117068